Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long‐term analysis of 132 patients
Open Access
- 18 October 2007
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 14 (11) , 995-999
Abstract
Objectives: In T1 bladder cancer (BC) multifocality, size of tumor (≥3 cm) and concomitant carcinoma in situ (CIS) are used to stratify patients' risk. We compared the long‐term results in patients with initial T1G3 bc treated with transurethral resection of the bladder (TURB), bacille Calmette‐Guérin (BCG) instillations and repeat resection with special regard to these clinical risk factors. The aim was to determine if they influence the outcome in the bladder sparing approach for initial T1G3 bc.Methods: One hundred and thirty‐two consecutive patients with initial T1G3 and no prior history of BC were identified. All patients completed six weekly adjuvant BCG instillations followed by control TURB. Follow‐up consisted of cystoscopy with bladder wash cytology every 3 months for 2 years and every 6 months thereafter.Results: Forty‐two percent of patients had residual disease, 65% developed recurrence of any stage and 41% had progression to muscle‐invasive disease. Cancer‐specific survival was 89% and 78% at 5 and 10 years, respectively. Only CIS was significantly correlated with all end points on multivariate analysis. While the presence of one or two risk factors was not related to recurrence, progression or cancer‐related death, the presence of all three risk factors predicted the latter.Conclusions: While no guideline has been established for the decision between cystectomy and bladder sparing, concomitant CIS and the presence of all three risk factors together seem to predict an adverse oncological outcome in the bladder sparing approach.Keywords
This publication has 18 references indexed in Scilit:
- A re‐staging transurethral resection predicts early progression of superficial bladder cancerBJU International, 2006
- The value of a second transurethral resection for T1 bladder cancerBJU International, 2006
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- The Case for Early Cystectomy in the Treatment of Nonmuscle Invasive Micropapillary Bladder CarcinomaJournal of Urology, 2006
- RESTAGING TRANSURETHRAL RESECTION OF HIGH RISK SUPERFICIAL BLADDER CANCER IMPROVES THE INITIAL RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPYJournal of Urology, 2005
- PRIMARY T1G3 BLADDER CANCER: ORGAN PRESERVING APPROACH OR IMMEDIATE CYSTECTOMY?Journal of Urology, 2004
- A Retrospective Analysis of 153 Patients Treated With or Without Intravesical Bacillus Calmette-Guerin for Primary Stage T1 Grade 3 Bladder Cancer: Recurrence, Progression and SurvivalJournal of Urology, 2003
- Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, 2002
- DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS?Journal of Urology, 2001
- RECURRENCE AND PROGRESSION OF STAGE T1, GRADE 3 TRANSITIONAL CELL CARCINOMA OF THE BLADDER FOLLOWING INTRAVESICAL IMMUNOTHERAPY WITH BACILLUS CALMETTE-GUERINJournal of Urology, 2000